Evidence map›Paper›PMID 27113048›Full record

Trial reportHypertension (Dallas, Tex. : 1979)2016

Chronic Nebivolol Treatment Suppresses Endothelin-1-Mediated Vasoconstrictor Tone in Adults With Elevated Blood Pressure.

Kyle J Diehl, Brian L Stauffer, Caitlin A Dow, Tyler D Bammert, Danielle L Brunjes, Jared J Greiner, Christopher A DeSouza

Registry-linked trialOpen access · bronzeAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Hypertension (Dallas, Tex. : 1979), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01395329 (Nebivolol and the Endothelin), which is not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01395329 phase4completednot on this map

Nebivolol and the Endothelin (ET)-1 System

TypeinterventionalSponsorUniversity of Colorado, BoulderRan2011 to 2016Enrolled42ConditionsPrehypertension, HypertensionArmsNebivolol, Metoprolol, Placebo, Forearm Blood Flow (FBF) response to BQ-123 (100 mol/min), FBF response to BQ-123 (100 nmol/min)+BQ-788(50 nmol/min)
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Kyle J DiehlFrom the Integrative Vascular Biology Laboratory, Department of Integrative Physiology, University of Colorado, Boulder (K.J.D., B.L.S., C.A.D., T.D.B., D.L.B., J.J.G., C.A.D.); Department of Medicine, University of Colorado, Denver (B.L.S., C.A.D.); and Department of Medicine, Denver Health Medical Center, CO (B.L.S.).
Brian L StaufferFrom the Integrative Vascular Biology Laboratory, Department of Integrative Physiology, University of Colorado, Boulder (K.J.D., B.L.S., C.A.D., T.D.B., D.L.B., J.J.G., C.A.D.); Department of Medicine, University of Colorado, Denver (B.L.S., C.A.D.); and Department of Medicine, Denver Health Medical Center, CO (B.L.S.).
Caitlin A DowFrom the Integrative Vascular Biology Laboratory, Department of Integrative Physiology, University of Colorado, Boulder (K.J.D., B.L.S., C.A.D., T.D.B., D.L.B., J.J.G., C.A.D.); Department of Medicine, University of Colorado, Denver (B.L.S., C.A.D.); and Department of Medicine, Denver Health Medical Center, CO (B.L.S.).
Tyler D BammertFrom the Integrative Vascular Biology Laboratory, Department of Integrative Physiology, University of Colorado, Boulder (K.J.D., B.L.S., C.A.D., T.D.B., D.L.B., J.J.G., C.A.D.); Department of Medicine, University of Colorado, Denver (B.L.S., C.A.D.); and Department of Medicine, Denver Health Medical Center, CO (B.L.S.).
Danielle L BrunjesFrom the Integrative Vascular Biology Laboratory, Department of Integrative Physiology, University of Colorado, Boulder (K.J.D., B.L.S., C.A.D., T.D.B., D.L.B., J.J.G., C.A.D.); Department of Medicine, University of Colorado, Denver (B.L.S., C.A.D.); and Department of Medicine, Denver Health Medical Center, CO (B.L.S.).
Jared J GreinerFrom the Integrative Vascular Biology Laboratory, Department of Integrative Physiology, University of Colorado, Boulder (K.J.D., B.L.S., C.A.D., T.D.B., D.L.B., J.J.G., C.A.D.); Department of Medicine, University of Colorado, Denver (B.L.S., C.A.D.); and Department of Medicine, Denver Health Medical Center, CO (B.L.S.).
Christopher A DeSouzaFrom the Integrative Vascular Biology Laboratory, Department of Integrative Physiology, University of Colorado, Boulder (K.J.D., B.L.S., C.A.D., T.D.B., D.L.B., J.J.G., C.A.D.); Department of Medicine, University of Colorado, Denver (B.L.S., C.A.D.); and Department of Medicine, Denver Health Medical Center, CO (B.L.S.). desouzac@colorado.edu.
University of Colorado Denver · US

Funding

Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
POSTGRADUATE TRAINING IN CARDIOVASCULAR RESEARCHT32HL007822 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI BUTTRICK, PETER N., LEINWAND, LESLIE ANNE · 1996 to 2023
$6.2M
NCATS NIH HHS UL1 TR001082NHLBI NIH HHS T32 HL007822
6 · The paper itself

Abstract

unlabelledEndothelin-1 (ET-1) plays a major role in the pathophysiology of hypertension and its associated cardiovascular risk. We tested the hypothesis that chronic nebivolol treatment reduces ET-1-mediated vasoconstrictor tone in adult humans with elevated blood pressure (BP). Furthermore, reducing ET-1 vasoconstrictor activity contributes to the improvement in endothelial vasodilator function associated with nebivolol treatment. Forty-two middle-aged adults with elevated BP (systolic BP ≥130 mm Hg or diastolic BP ≥85 mm Hg) completed a 3-month, double-blind, randomized, placebo controlled trial: 14 received nebivolol (8 men/6 women; 5 mg per day); 14 received metoprolol succinate (9 men/5 women; 100 mg per day); and 14 received placebo (9 men/5 women). Forearm blood flow (plethysmography) responses to selective (BQ-123: 100 nmol/min; 60 minutes) and nonselective (BQ-123+BQ-788 [50 nmol/min]; 60 minutes) ET-1 receptor blockade, as well as acetylcholine (4.0, 8.0, and 16.0 μg per 100 mL of tissue per minute) in the absence and presence of nonselective ET-1 receptor blockade were determined before and after each treatment intervention. Forearm blood flow responses to BQ-123 and BQ-123+BQ-788 were similarly and significantly elevated (≈30% and 60%, respectively) from baseline in all 3 groups. Nebivolol, but not metoprolol or placebo, therapy resulted in a marked (≈25% and 45%; P<0.05) reduction in forearm blood flow response to BQ-123 and BQ-123+BQ-788. Moreover, after nebivolol therapy only, vasodilator response to acetylcholine was not significantly increased by ET-1 receptor blockade. These results demonstrate that nebivolol, but not metoprolol, treatment reduces ET-1-mediated vasoconstrictor tone in adult humans with elevated BP. In addition, nebivolol-induced reduction in ET-1-mediated vasoconstrictor tone underlies the favorable effects of this β-blocker on endothelial vasodilation. CLINICAL

trial registrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT01395329.

Indexed as

Analysis of VarianceBlood Pressure DeterminationDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleEndothelin-1FemaleFollow-Up StudiesHumansHypertensionMaleMiddle AgedNebivololReference ValuesRisk AssessmentTime FactorsEndothelin-1NebivololVasodilator Agentsblood pressureendothelin-1metoprololnebivololvasoconstriction

Identifiers

PMID27113048
PMCPMC4871319
OpenAlexW2343313313

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.